AAA Clinical Trial
Official title:
NHS AAA Screening Programme Data Linkage With HES and ONS Datasets
NCT number | NCT03407664 |
Other study ID # | 0652 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2020 |
Est. completion date | January 1, 2021 |
Verified date | January 2020 |
Source | University of Leicester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
An abdominal aortic aneurysm (AAA) is a dilation of the aorta, defined as an aortic diameter
of ≥3cm. It is a significant cause of death internationally and in England each year causes
c.4,000 deaths with 8,000 patients undergoing preventative surgery. AAA are often
asymptomatic and there is a latent period between development and rupture. This represents an
opportunity to screen by ultrasound which has been shown in trials to reduce AAA related
mortality by half.
In England this evidence is based on a randomised trial data from the late nineties, however,
since these data were published the number of men identified with AAA has fallen to a current
prevalence of just over 1%. Furthermore, similarly designed randomised trials in Western
Australia demonstrated no meaningful differences in AAA or cardiovascular deaths. The first
aim of our research is to follow men who have been screened for AAA in England in order to
establish the medium (5 years) and long term (10+ years) impact of AAA screening on the risk
of a AAA, cardiovascular and all-cause morbidity/mortality in a non-trial setting. Men with
sub-aneurysms will be examined (Aorta=2.5-2.9cm) as several studies suggest this group is at
risk of late rupture.
The role of patient pathways to improve uptake of the screening programme will be examined.
Current data suggests that the most 'deprived' men in England are the least likely to turn up
for screening but the most likely to have an abdominal aneurysm. Outcomes in this group will
be analysed including the benefit of a new patient pathway to improve uptake nationally.
Lastly, several large studies have demonstrated that a larger aortic diameter may be
associated with cardiovascular risk. The addition of aortic diameter to current risk
prediction models could improve the accuracy of these models and will be examined.
Status | Not yet recruiting |
Enrollment | 1000000 |
Est. completion date | January 1, 2021 |
Est. primary completion date | January 1, 2021 |
Accepts healthy volunteers | |
Gender | Male |
Age group | 65 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. All men invited to the NHS AAA screening programme in England between the period of 2013-2017 2. Aged 65 years of age at the time of their invitation to the NHS AAA screening programme 3. All men who have consented for their data to be used for the purposes of research Exclusion Criteria: - 1. All men who do not consent for their data to be used for the purposes of research |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Leicester | Leicester |
Lead Sponsor | Collaborator |
---|---|
University of Leicester |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AAA related mortality in men invited for AAA screening | Mortality | 10 years | |
Primary | AAA related morbidity in men invited for AAA screening | Admissions to Hospital | 10 years | |
Secondary | Medium term mortality | Mortality (number of deaths) | 5 years | |
Secondary | Cardiovascular risk in men screened for AAA | Combined events (mortality and morbidity) | 10 years | |
Secondary | Medium term morbidity | Admissions to Hospital | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05064540 -
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
|
N/A | |
Completed |
NCT03762525 -
Iliac Branch Device Movement During Cardiac Cycle (IBD-dynamics)
|
N/A | |
Not yet recruiting |
NCT02843854 -
Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms
|
Phase 1 | |
Completed |
NCT04080557 -
Abdominal Aortic Aneurysm Patients Remain at Risk for Delirium on the Surgical Ward After Intensive Care Unit Dismissal
|
||
Recruiting |
NCT02179801 -
Screening Cardiovascular Patients for Aortic aNeurysms (SCAN)
|
N/A | |
Recruiting |
NCT05376514 -
Central Blood Pressure and Variability Evaluation
|
||
Active, not recruiting |
NCT05133492 -
First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA)
|
N/A | |
Terminated |
NCT02461524 -
Endurant Evo International Clinical Trial
|
N/A | |
Terminated |
NCT02485496 -
E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms
|
||
Not yet recruiting |
NCT05409118 -
JAGUAR Trial (Outside United States; OUS): ObJective Analysis to GaUge EVAR Outcomes Through Randomization
|
N/A | |
Active, not recruiting |
NCT02692664 -
Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft
|
||
Terminated |
NCT02393716 -
Endurant Evo US Clinical Trial
|
N/A |